Texas HB3717 establishes a grant program to fund FDA drug development trials with ibogaine for opioid use disorder and other conditions.

HB3717 creates a grant program to fund public-private partnerships for FDA drug development trials with ibogaine, aiming to secure FDA approval for treating opioid use disorder, co-occurring substance use disorder, and other neurological or mental health conditions. The Health and Human Services Commission will administer the grant program, establish trial sites, and select an institutional review board. Applicants must match state funding and submit detailed trial plans, including recruitment, screening, and aftercare protocols.

Texas HB3717 establishes a grant program to fund FDA drug development trials with ibogaine for opioid use disorder and other conditions.

HB3717 creates a grant program to fund public-private partnerships for FDA drug development trials with ibogaine, aiming to secure FDA approval for treating opioid use disorder, co-occurring substance use disorder, and other neurological or mental health conditions. The Health and Human Services Commission will administer the grant program, establish trial sites, and select an institutional review board. Applicants must match state funding and submit detailed trial plans, including recruitment, screening, and aftercare protocols.